Analyst Upgrades: Amazon.com, Inc., TherapeuticsMD Inc, and Marriott International Inc

Analysts upwardly revised their ratings and price targets on Amazon.com, Inc. (NASDAQ:AMZN), TherapeuticsMD Inc (NYSEMKT:TXMD), and Marriott International Inc (NASDAQ:MAR)

by Josh Selway

Published on Dec 8, 2015 at 9:19 AM

Analysts are weighing in on e-tailer Amazon.com, Inc. (NASDAQ:AMZN), women's health issue TherapeuticsMD Inc (NYSEMKT:TXMD), and hotelier Marriott International Inc (NASDAQ:MAR). Here's a quick roundup of today's bullish brokerage notes on AMZN, TXMD, and MAR. 

  • AMZN is positioned 1.1% lower ahead of the open, despite some high praise from Pacific Crest. The firm gave the stock a "buy" rating, even though it's already more than doubled in 2015, while setting its price target at $800 -- a roughly 19% premium to Monday's close at $669.83, and in uncharted territory. More broadly, the analysts said "e-commerce can be at least 30% of total retail sales in the next five years," compared to 7% currently. Pacific Crest certainly isn't alone in its bullish outlook, with 82% of all other brokerage firms calling Amazon.com, Inc. a "buy" or better. Option traders, though, are much more bearish. AMZN's 10-day put/call volume ratio at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) stands at 1.05, higher than 84% of all other readings from the past year. This points to a stronger-than-usual preference for put buying compared to call buying
  • TXMD is set to shoot close to 40% higher at the open, after the company announced positive top-line results for its dyspareunia treatment, TX-004HR, in a late-stage study. The security has since received three price-target increases, with Guggenheim setting the bar the highest at $33 -- a dramatic move, considering the shares closed Monday at $6.53. What's more, it's been a disappointing few months for TherapeuticsMD Inc, which has shed 26.1% since its late-July annual high of $8.83. This underperformance has brought in the short sellers. Over 18% of TXMD's float is sold short, accounting for an astonishing 26 days' worth of buying power, at the stock's normal daily volumes. 
  • MAR will look to use some bullish attention from Berenberg to make up some of its 10.9% year-to-date decline. The brokerage firm started the security with a "buy" rating and a $90 price target -- which would mark a record high -- while adding Marriott International Inc to its "Alpha List." If the shares do rally, speculators could be in for some pain. MAR's Schaeffer's put/call open interest ratio (SOIR) stands at 3.16, which outranks 89% of all other readings from the past year. Put simply, short-term option traders are much more put-skewed than normal. MAR settled at $69.50 on Monday. 
Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


  
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


Research Exposes Shortcut to Stock Market Wins
A simple way to stop picking losers, and start cashing in like Wall Street's elite.
Cannabis Stock Rally Cut Short after Downgrade
Aurora Cannabis did receive a price-target hike from Jefferies, though
Vaccines, China Trigger Roller Coaster Week for Stocks
Moderna's vaccine captured the attention of Wall Street
Research Exposes Shortcut to Stock Market Wins
A simple way to stop picking losers, and start cashing in like Wall Street's elite.